Overview
- Editors:
-
-
Margaret Hanausek
-
AMC Cancer Research Center, Denver
-
Zbigniew Walaszek
-
AMC Cancer Research Center, Denver
Access this book
Other ways to access
Table of contents (30 protocols)
-
-
Multiple Markers: Principles and Guidelines
-
-
-
-
- George P. Hemstreet III, Robert E. Hurst, Rebecca B. Bonner
Pages 37-60
-
- Gordon F. Schwartz, Roland Schwarting
Pages 61-91
-
Immunodiagnosls of Cancer: Serum and Tissue Markers
-
-
- Tina J. Hieken, Rajeshwari R. Mehta
Pages 95-102
-
- Margaret Hanausek, Zbigniew Walaszek, Ute Sherman, Jerzy T. Klijanienko
Pages 103-114
-
- Jonathan F. Head, Robert L. Elliott
Pages 115-125
-
- David M. Parham, Hallie Holt
Pages 127-142
-
- William E. Grizzle, Russell B. Myers, Upender Manne, Sudhir Srivastava
Pages 143-160
-
- William E. Grizzle, Russell B. Myers, Upender Manne, Cecil R. Stockard, Lualhati E. Harkins, Sudhir Srivastava
Pages 161-179
-
- Rebecca B. Bonner, Robert E. Hurst, Jian Yu Rao, George P. Hemstreet
Pages 181-205
-
Cytogenetic Markers
-
Front Matter
Pages 207-207
-
- Susana C. Raimondi, Susan Mathew, Ching-Hon Pui
Pages 209-227
-
- Kevin A. Hahn, Penny K. Riggs
Pages 229-238
-
- Kevin A. Hahn, Penny K. Riggs
Pages 239-243
-
- Penny K. Riggs, Kevin A. Hahn
Pages 245-254
-
- Ruth W. Craig, Dorothy R. Belloni, Ernest S. Kawasaki, Norman B. Levy
Pages 255-266
About this book
The development of cancer is a slow process and it very often takes a number of years before a tumor becomes clinically evident. No current te- nique is sensitive and specific enough to detect tumors at their earliest stage, i. e. , when the tumor is smaller than one billion cells. Consequently, the d- ease is usually diagnosed in an advanced state, very often when it is already beyond the reach of therapeutic strategies. This is the main stumbling block to the secondary prevention that would reduce cancer mortality. There is hope, however, because in the last decade we have witnessed an explosion of reports dealing with tumor markers. In many instances, simple, noninvasive diagnostic tests are becoming available to detect the early signs ofneoplasia. Interest in early detection of neoplasia is growing among those basic scientists, cli- cians, and health professionals who realize that progress in reducing cancer mortality is dependent to a great degree on its early detection and prevention. Some disappointment usually accompanies these discoveries, because what at first glance proves to be promising, is in many instances, applicable only to a limited number of cases. What is the cause of these failures? The answer may be that cancer is a multitude of neoplastic diseases in which endogenous and exogenous etiologic factors contribute either sim- taneously or over a lifetime to the development of disease.
